NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/31/2024
Back to search
Official data from USPTO
CRINETICS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
CRINETICS PHARMACEUTICALS
ST13
US500000097844125Class
5, 42
Filing
97844125
Registration
7635112
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
12/31/2024
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
03/17/2023
Registration date
12/31/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/31/2024
Last transaction
12/31/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
12/07/2018
First use in commerce
12/07/2018
Drawing code
4
Owner type
03
Owner location
San Diego, CA
Examiner
STOIDES, KATHERINE
Law office
L10
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Crinetics Pharmaceuticals, Inc.
Representatives
Danny M. Awdeh FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for modulating neuropeptides and G-protein coupled receptors (GPCRs); pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in treating endocrine disorders and endocrine related diseases; pharmaceutical preparations for targeting neuropeptide receptors; pharmaceutical preparations for the treatment of canceracromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismcarcinoid syndromecongenital adrenal hyperplasiahypercalcemiachronic painhyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; therapeutic preparations for the treatment of ocular diseases and disordersmetabolic diseases and disordershormonal diseases and disordersreproductive diseases and disordersbone diseases and disordersdigestive diseases and disordersgastroenterological diseases and disordersthyroid diseases and disorders
Class 42
Medical research services; scientific research and development; pharmaceutical research and development; therapeutic research and developmentresearch and development of therapeutic preparations; research and development in the field of oncology; medical research for treating cancerendocrine disordersacromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic painhypercalcemiahyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; pharmaceutical research for treating cancerendocrine disordersacromegalyneuroendocrine tumorsCushing's Diseasehyperinsulinismchronic painhypercalcemiahyperparathyroidismpolycystic kidney diseaseGrave's diseasethyroid eye diseasethyroid ophthalmopathydiabetesobesityinsulinomahypoglycemiaandrogen deficiencyinfertilitythyroid cancergrowth hormone deficiencyhypoparathyroidismnonfunctional pituitary adenomaspolycystic liver diseasetype two diabetes; therapeutic researchresearch of therapeutic preparations for ocular diseases and disordersmetabolic diseases and disordershormonal diseases and disordersreproductive diseases and disordersbone diseases and disordersdigestive diseases and disordersgastroenterological diseases and disordersthyroid diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and therapeutics
Publications
History of USPTO decisions and trademark events.
30 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/31/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/09/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/09/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/13/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/13/2024
IUAF
USE AMENDMENT FILED
09/12/2024
EISU
TEAS STATEMENT OF USE RECEIVED
09/12/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/12/2024
EX1G
SOU EXTENSION 1 GRANTED
09/12/2024
EXT1
SOU EXTENSION 1 FILED
09/12/2024
EEXT
SOU TEAS EXTENSION RECEIVED
09/12/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/26/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/28/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/28/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/28/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/30/2024
PUBO
PUBLISHED FOR OPPOSITION
01/30/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/22/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
12/19/2023
ALIE
ASSIGNED TO LIE
12/19/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/18/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
12/18/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/18/2023
DOCK
ASSIGNED TO EXAMINER
12/13/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
10/09/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
10/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/09/2023
NWAP
NEW APPLICATION ENTERED
03/21/2023
Continuous trademark protection
Get notified about every new filing that threatens CRINETICS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.